Dear Sir
Phlebitis is a well-described adverse effect of intravenous (IV) administration of amiodarone, with reported incidence ranging from 11% to 85%. [1] [2] [3] [4] Risk factors for amiodarone-induced phlebitis (AIP) are many and include peripheral infusion, concentrations exceeding 2 mg/mL, 2,3 higher dose of amiodarone administered via a single line, 3 the absence of in-line filters, 2 suboptimal aseptic technique during line insertion, absence of postinfusion line flushing, poor vein condition, older age, female sex, administration errors, and the concurrent administration of other medications known to cause phlebitis. 3, 4 Clinical practice in our hospital reduces the importance of some of these risk factors, via IV infusion pumps with dose error reduction software and inline filters in all giving sets. Despite this, cardiology nursing staff perceived a high incidence of AIP and communicated this to the pharmacy department. This combined with marked variation in the reported incidence of AIP and that some risk factors are no longer relevant to contemporary clinical practice prompted this quality improvement study. In this letter, we present the recorded incidence of AIP, contributing factors, and its management among 95 patients receiving IV amiodarone. These patients were identified through retrospective review of the digital medical records of 2104 cardiology patients admitted between 1 July 2015 and 31 January 2016. This audit was approved as a clinical improvement project by the institution's quality improvement committee (GEKO11186), which considered it exempt from requiring human research ethics approval.
There were 18 patients (19%) with documented phlebitis secondary to IV amiodarone (mean age 69 years, 50% female, Table 1 ). Of these, 16 (89%) had received the drug through a peripheral and 2 (11%) through a central venous catheter. The crude odds ratio (OR) for phlebitis with amiodarone given via a peripheral relative to central venous catheter was 6.10 (95% confidence interval (CI): 1.22-30.36, p = 0.01). This reduced to 5.34 (95% CI: 1.05-27.32, p = 0.02) after adjustment for sex. This is consistent with the mechanism by which amiodarone causes phlebitis, as peripheral veins are narrower and have reduced blood flow compared to central veins. 1, 5 The crude OR for phlebitis occurring in females relative to males was 3.53 (95% CI: 1.16-10.70, p = 0.02).
Despite the dose error reduction software, 11 patients received amiodarone under conditions inconsistent with our hospital guidelines. These were all among patients receiving amiodarone via a peripheral cannula with reasons of exceeding the maximum recommended concentration (n = 7), infusion rate (n = 3), or infusion duration (n = 1). However, there were no reports of phlebitis among these patients. There were seven patients where it could not be determined whether the entire infusion conformed to our institution's guidelines due to infusion initiation offsite. Peripheral cannulas were used for five of these patients, and phlebitis was noted among three of these patients.
Phlebitis management was documented for 14 cases (78%). Management included ⩾1 of antibiotics (41%), glycerol and ichthammol paste (23%), cold compress (5%), and limb elevation or analgesia (32%).
Our findings demonstrate that phlebitis remains a common adverse effect of IV amiodarone administration and provides data from a contemporary clinical setting where in-line filters are standard and dose error reduction software decreases the risk of excessive concentrations and infusion rates. 
